Healthcare Industry News: demineralized bone matrix
News Release - August 23, 2006
PrimeCell(TM) Therapeutics Partners with Regeneration Technologies, Inc. to Co-Develop Stem Cell Product for Orthopedic ApplicationsIRVINE, Calif.--(HSMN NewsFeed)--Aug. 23, 2006--PrimeCell(TM) Therapeutics LLC (www.primecelltherapeutics.com) today announced an agreement with Regeneration Technologies, Inc. (RTI) (Nasdaq:RTIX ), the Florida-based processor of orthopedic, cardiovascular and other biologic implants, to pursue orthopedic applications using PrimeCell(TM) Therapeutics' germ cell reprogramming technology.
The two companies will develop and evaluate a protocol for utilizing reprogrammed germ line stem cells in conjunction with biological implants for potentially increased therapeutic value of orthopedic grafts. The research will focus on the use of stem cells isolated from donated material, mixed with demineralized bone matrix (DBM) -- working toward future research to address their reintroduction into the body of an orthopedic patient.
Future studies could include other clinical applications that would represent additional viable markets for this type of technology.
"This is a huge step forward in our pursuit of progressing research from the lab to the clinic in a timely manner in order to provide patients with effective stem cell-based therapies," said Thomas C.K. Yuen, PrimeCell Therapeutics chairman and CEO. "Regeneration Technologies is a leader in developing innovative, healing solutions. We're excited to partner with such an innovative company."
"PrimeCell technology is an exciting and novel step forward in the area of stem cell science and regenerative medicine," said Brian K. Hutchison, RTI's Chairman, President and CEO. "The possibilities are intriguing and promising. This should be an exciting partnership for both organizations and, even more, for those most likely to benefit from our work."
RTI is a leader in tissue-based innovations that are used to repair and promote the natural healing of human bone and other tissues. RTI prepares donated human and bovine tissue for transplantation after extensive testing and screening, precision shaping and proprietary, validated sterilization processes. Implants are used for orthopedic, oral maxillofacial, urinary and cardiovascular surgeries.
PrimeCell Therapeutics researchers have isolated adult stem cells from the germ line and reprogrammed them to exhibit a greater plasticity. These adult cells already have been therapeutically reprogrammed into human heart, brain, bone and cartilage cells.
About PrimeCell(TM) Therapeutics LLC
PrimeCell(TM) Therapeutics LLC, a PrimeGen Biotech company, is devoted exclusively to adult stem cell reprogramming. Its next generation stem cell -- PrimeCell(TM) -- is the first adult, non-embryonic stem cell capable of transforming into any cell type found in the body. The company has introduced its murine model and initial human results for PrimeCell at several global stem cell conferences. Its innovative science and unique approach qualify PrimeCell Therapeutics as one of the preeminent biotechnology firms within the emerging field of regenerative medicine.
About Regeneration Technologies, Inc.
RTI processes allograft and xenograft tissue into shaped implants for use in orthopedic and other surgeries with a commitment to science, safety and innovation. RTI also holds patents on the BioCleanseŽ process, the only proven tissue sterilization process validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the tissue. The company has distributed more than 700,000 implants sterilized with the BioCleanse process with zero incidence of infection. RTI is accredited by the American Association of Tissue Banks and was named a 2004 Technology Pioneer by the World Economic Forum.
Except for historical information, any statements made in this press release about the company's anticipated financial results, future operational results or regulatory approvals are forward-looking statements subject to risks and uncertainties such as those described in the company's public filings on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or by visiting RTI's web site at www.rtix.com or the SEC's web site at www.sec.gov.
Source: PrimeCell Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.